The patient's treatment of COVID-19 is completely free, and the patient does not need to bear any medical expenses. At present, it is also pointed out that seven drugs outside the medical insurance catalogue can be included in the new medical insurance catalogue in 2020, including drugs for treating respiratory diseases related to COVID-19. In addition, experts said that the medical insurance catalogue adjustment plan will bring the drugs related to new coronary pneumonia into a new scope, which will provide important support for the normalization of epidemic prevention and control in COVID-19. Therefore, all drugs in COVID-19 may be included in medical insurance in the later stage, and people need to pay attention to the adjustment scope of medical insurance catalogue in time.
For drugs out of the catalogue, in the evaluation, calculation and determination of the payment scope of medical insurance fund, the current economic and social development level of China, the affordability of medical insurance fund and insured personnel and other factors are comprehensively considered to set compliance. Stay basic? Positioning of technical standards to ensure that the negotiated payment standards meet expectations. For the drugs in the catalogue, experts will be specially organized to review, and the varieties that have entered the catalogue without negotiation and have high prices or fees will be negotiated to reduce prices, so as to guide the drug payment standards in the catalogue to gradually return to rationality. At the same time, through measures such as drug dispensing with low clinical value, especially centralized procurement with quantity in recent years? Trade quantity for price? Further squeeze the water of drug price and realize it? Change the birdcage? To ensure the safety of the fund.
Different from previous rounds of adjustment. All the drugs on the market? This year, the declaration system was implemented for the first time, that is, off-balance-sheet drugs that meet the conditions listed in this year's adjustment plan can be included in the adjustment scope. The adjustment range of drugs outside the catalogue has been realized from? Audition? Where to? Preferred? Change. ?
According to preliminary estimates, we can make room for funds by negotiating price reduction and transferring catalogues. Because we strictly control the economy of drugs in the process of catalogue adjustment, most of the newly added 1 19 drugs (96 exclusive and 23 non-exclusive) are exclusive drugs for price reduction negotiation. It is estimated that the increased fund expenditure in 20021is basically equivalent to the space vacated by drug negotiation and transfer. At the same time, this drug negotiation agreement is valid for two years. Two years later, we will adjust the payment standard again according to the actual sales situation to ensure the smooth operation of the fund.
From the perspective of patient burden, it is estimated that the patient burden will be reduced by about 28 billion yuan in 20021year through negotiation of price reduction and medical insurance reimbursement. It can be said that this is a relatively large national medical subsidy. In addition, the new catalogue will be officially implemented on March 1, 202 1, and relevant medical insurance can be consulted if necessary.